SPEEDBioSystems TURBO293 Transfection Reagents
ID: NOI-NIAID-25-2254745Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/9c7bf361d36c47839b1124424e4803cb/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a procurement contract with SPEED BioSystems, LLC for the acquisition of TURBO293 Transfection Reagents. The requirement includes 46 units of the TURBO293 TRANSFECTION REAGENT (20ML), which are critical for ongoing research and development activities at the Vaccine Research Center in Bethesda, Maryland. This procurement is being conducted on a sole-source basis due to SPEED BioSystems, LLC being the sole owner and developer of the required reagents, ensuring continuity and compatibility with existing protocols. Interested vendors may submit their capabilities statements to Jessica Emerson at jessica.emerson@nih.gov by the specified deadline for consideration, although the government is under no obligation to award a contract based on the responses received.

    Point(s) of Contact
    Jessica Emerson
    (406) 802-6324
    jessica.emerson@nih.gov
    Jesse Weidow
    weidowjd@niaid.nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    SPEEDBioSystems TURBO293 Transfection Reagents
    Currently viewing
    Solicitation
    Similar Opportunities
    GeminiBio GemCell TM Plus Xeno free Reagents.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a fixed-price contract for the supply of GeminiBio GemCell TM Plus Xeno free reagents, essential for the Center for Cellular Engineering's operations in Bethesda, Maryland. The procurement aims to secure a reliable source of reagents critical for manufacturing human cell and tissue-based products used in clinical trials, as the Center has validated GeminiBio's products for compatibility with its processes. This acquisition is vital to prevent treatment delays for patients involved in clinical trials, as switching vendors would necessitate costly and time-consuming requalification. Interested parties capable of providing similar products must submit a capability statement by January 26, 2025, to Emeka Onyejekwe at emeka.onyejekwe@nih.gov.
    ANTIBODY REAGENT KITS
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking to procure antibody reagent kits from Abcam, Inc. for a technology development project aimed at validating results from mass cytometry panels used to study the human immune system. These antibody kits are crucial for phenotyping the immunome, which is essential for understanding both normal and pathogenic immune responses in various diseases. Interested vendors capable of providing comparable services are invited to submit a capabilities statement via the NIAID electronic Simplified Acquisition Submission System (eSASS) by 9:00 AM EST on January 21, 2025. For further inquiries, vendors may contact Maliaka Pinkney at maliaka.pinkney@nih.gov or Jesse D Weidow at weidowjd@niaid.nih.gov.
    Sebia Inc. Hydrasys 2 Reagents for the Department of Laboratory Medicine
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure Sebia Inc. Hydrasys 2 reagents through a sole-source contract for the Department of Laboratory Medicine. This acquisition aims to secure essential reagent kits, quality control materials, and supplies necessary for electrophoresis testing, which is critical for monitoring patients with B-cell malignancies and central nervous system diseases. The Sebia reagent kits are uniquely designed for compatibility with the existing Sebia Hydrasys 2 analyzers, ensuring high-quality patient care within the Chemistry Service. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by January 31, 2024, at 6:30 AM EST, as this is not a request for quotations.
    Brand name or equal, Reagent needed for amplification of DNA for next generation sequencing in high-throughput assay for chromatin for The National Center for Advancing Translational Sciences (NCATS)
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) is seeking suppliers for a brand name or equal reagent necessary for the amplification of DNA for next-generation sequencing in high-throughput assays for chromatin, specifically for the National Center for Advancing Translational Sciences (NCATS). The procurement aims to acquire the NEBNext Ultra II Q5 Master Mix in a bulk order of 500 mL, which is critical for optimizing protocols and facilitating high-throughput screening. This reagent is essential for advancing medical research and enhancing the development of diagnostics and therapeutics across various human diseases. Interested vendors must submit their capability statements and relevant documentation by January 22, 2025, at 9 am Eastern Time to Giuliana Faller at giuliana.faller@nih.gov.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Brand-Name or Equal, Acquisition of Agilent Bioanalyzer 5200 Fragment analyzer system for ETB Group at NCATS.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking responses for the acquisition of a Brand-Name or Equal Agilent Bioanalyzer 5200 Fragment Analyzer system for the ETB Group at the National Center for Advancing Translational Sciences (NCATS). The procurement includes the Bioanalyzer system, a computer and monitor, controller and analysis software, capillary array, and installation/familiarization services, which are crucial for nucleic acid quantification and characterization in biomedical research. This advanced equipment is essential for high-throughput separation and quantification of DNA and RNA, supporting NIH's mission to enhance health and reduce illness through innovative medical research. Interested vendors must submit their capability statements by January 27, 2025, at 9 am Eastern Time, to Contract Specialist Giuliana Faller at giuliana.faller@nih.gov.
    Acquisition of SomaScan 7K and 11K Assay Kits
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure fifty-nine (59) SomaScan 7K and/or 11K Assay Kits on a sole source basis from SomaLogic Operating Co., Inc. This acquisition is intended to support the Center for Human Immunology, Inflammation, and Autoimmunity (CHI) in their systems biology research, which involves measuring a wide range of proteins in various human biological samples to enhance understanding of the immune system and related diseases. The procurement aligns with federal initiatives to advance health science research capabilities, with an estimated delivery date for the products set for December 20, 2024, and a performance period from February 21, 2025, to February 20, 2026. Interested vendors may contact Kathy Song at kathy.song@nih.gov for further information and must submit their capabilities statements within 15 days of this notice.
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.
    SERVICE AGREEMENT FOR THERMO ELECTRON LABORATORY EQUIPMENT (AMBIS 2247584)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting quotes for maintenance agreements on Thermo Electron laboratory equipment, critical for research involving complex proteomic data. The procurement, identified by solicitation number RFQ-NIAID-25-2247584, requires comprehensive service plans for various mass spectrometry instruments, ensuring prompt maintenance response times, priority technical support, and regular preventive maintenance visits. This equipment is essential for analyzing high-value samples in ongoing research projects, and the contract period spans from March 19, 2025, to March 18, 2026. Interested vendors must submit their quotes electronically by December 30, 2024, and can contact Kimberly Rubio at kimberly.rubio@nih.gov for further information.
    SOURCES SOUGHT: Mass Spectrometry Reagents
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), is seeking qualified small business sources for the procurement of specialized Mass Spectrometry Reagents aimed at advancing research on Alzheimer’s Disease and related dementias. The objective is to establish a national resource of isogenic induced pluripotent stem cell (iPSC) lines to study genetic mutations associated with these diseases, thereby accelerating mechanistic discovery. This procurement is critical for enhancing the understanding of Alzheimer’s disease mechanisms and includes specific requirements for HPLC columns and related supplies, with the first delivery expected by July 7, 2025, and additional options extending to July 2027. Interested parties should submit their capability statements to Rashiid Cummins at Rashiid.Cummins@nih.gov by January 21, 2025, at 3:00 PM Eastern Time.